2 Denosumab, a monoclonal antibody targeting RANKL, is a key therapy for conditions like osteoporosis and metastatic bone disease, working by inhibiting osteoclast activity to reduce bone resorption ...
Osteoporosis, a condition that weakens bones ... A 2024 study revealed that PM2.5 can lead to overproduction of osteoclasts, cells that break down bone tissue, and to lower production of ...
[94] PTHs also may not need to stimulate osteoclasts and mobilize BMUs to ... They all received 800 U of vitamin D and 1500 mg of calcium daily. By the end of 2 years, the overall (cortical ...